Figure 4.

Odds of improvement or deterioration in NYHA functional class during first 52 weeks as a result of treatment with empagliflozin. Shown are the odds ratios for empagliflozin vs placebo for improvement in NYHA functional class (top, shown in blue) and for deterioration in NYHA functional class (bottom, shown in red). An odds ratio of 1.3 indicates 30% higher odds of improvement, whereas an odds ratio of 0.7 indicates 30% lower odds of deterioration. Patients who died, were lost to follow-up, or declined consent were assigned worst rank, but very similar results were seen when the analysis was repeated without these worst rank assignments. P values represent the significance of the differences between the 2 treatment groups. NYHA indicates New York Heart Association.